Get the Stockscreener App
0.831
3.57%
-0.0308
Pre-market:
.80
-0.031
-3.73%
Imunon Inc Stock (IMNN) Latest News
Can IMUNON's DNA Vaccine Outperform mRNA COVID Shots? New Clinical Data Reveals Key Advantages - StockTitan
Imunon (IMNN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Imunon Inc [IMNN] Shares Jump Approximately 66.98% Over the Year - Knox Daily
The time has not yet come to remove your chips from the table: Imunon Inc (IMNN) - SETE News
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 - The Manila Times
IMUNON, Inc. to Announce Full Year 2024 Financial Results on February 27, 2025 - Nasdaq
New Phase II data confirm promise of Imunon’s IMMN-001 - The Pharma Letter
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer - GlobeNewswire
Imunon Announces Translational Data From Phase 1/2 Ovation 2 Study Of Imnn-001 In Advanced Ovarian Cancer - Marketscreener.com
Ovarian Cancer Breakthrough? New Drug Shows 13-Month Survival Advantage in Clinical Trial - StockTitan
IMUNON names Douglas Faller as chief medical officer - MSN
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
Imunon names industry vet Douglas Faller as CMO - The Pharma Letter
Imunon Appoints Dr. Douglas Faller as CMO - TipRanks
Imunon director Donald Braun acquires $29,480 worth of shares - MSN
IMNN: Gearing Up to Initiate Phase 3 Ovarian Cancer Trial in 1Q25 - Research Tree
Imunon’s (IMNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Analyzing Imunon (NASDAQ:IMNN) & Unicycive Therapeutics (NASDAQ:UNCY) - Defense World
Biotech's Target Price 183.757% Higher Than Current - Streetwise Reports
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer - GlobeNewswire
IMUNON Secures FDA Alignment for Phase 3 Ovarian Cancer Immunotherapy Manufacturing Strategy - StockTitan
Imunon, Inc. (NASDAQ:IMNN) Short Interest Update - Defense World
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001 - The Manila Times
IMUNON Announces Continued Strong Improvement in Overall - GlobeNewswire
IMUNON's Ovarian Cancer Drug Shows Improved Survival Data in Phase 2 Trial, Phase 3 Planned - StockTitan
Critical Review: Sernova (OTCMKTS:SEOVF) & Imunon (NASDAQ:IMNN) - Defense World
Imunon faces Nasdaq delisting over share price rule By Investing.com - Investing.com Canada
Imunon faces Nasdaq delisting over share price rule - Investing.com
D. Boral Capital Reaffirms Buy Rating for Imunon (NASDAQ:IMNN) - Defense World
Imunon shares hold as analyst backs stock target, buy rating post FDA meet - Investing.com UK
IMNN: Comes to Alignment with FDA Regarding Phase 3 Protocol for IMNN-001 - Smartkarma
Imunon announces results from End-of-Phase 2 meeting with FDA for IMNN-001 - TipRanks
IMUNON Announces Results from its End-of-Phase 2 Meeting - GlobeNewswire
IMUNON's Cancer Drug Shows 35% Survival Boost, FDA Backs Phase 3 Trial | IMNN Stock News - StockTitan
FY2024 EPS Estimates for Imunon Boosted by Zacks Small Cap - Defense World
Analysts Set Expectations for Imunon Q1 Earnings - Defense World
Imunon, Inc. (NASDAQ:IMNN) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Imunon reveals promising ovarian cancer study results - Investing.com India
Earnings call: Imunon reveals promising ovarian cancer study results By Investing.com - Investing.com UK
Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ... - Yahoo Finance
Imunon, Inc. Reports Q3 2024 Earnings and Progress - TipRanks
Imunon Inc (IMNN) Quarterly 10-Q Report - Quartzy
Imunon presents data from Phase 2 OVATION 2 clinical trial - TipRanks
IMUNON Presents Positive Data from Phase 2 OVATION 2 - GlobeNewswire
IMUNON's Cancer Drug Shows 35% Survival Boost in Phase 2 Ovarian Cancer Trial | IMNN Stock News - StockTitan
Imunon sees cash runway into 3Q25 - TipRanks
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
IMUNON INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Imunon (IMNN) to Release Quarterly Earnings on Thursday - MarketBeat
IMUNON to Hold Third Quarter 2024 Financial Results and - GlobeNewswire
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):